Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV (p)


Share Price (p)


Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 81.62%
Worldwide Healthcare (Ordinary Share) NAV 88.82%
FTSE World 36.74%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement


Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 1315.0p -7.1% 1415.00p 1400.00p
29 Jul
110% 1.14%

Discrete performance % over

Fund / BenchmarkAug '11
Jul '12
Aug '12
Jul '13
Aug '13
Jul '14
Worldwide Healthcare (Ordinary Share) Price10.9541.2215.91
Worldwide Healthcare (Ordinary Share) NAV15.9032.7822.70
FTSE World2.0925.706.55

Discrete performance over

Discrete Performance

Top 10 Holdings

Roche Holding AG 6.40%
HCA Holdings Inc 3.80%
Bristol-Myers Squibb Company 3.70%
MYLAN 3.60%
AbbVie Inc 3.60%
Merck & Co. Inc. 3.50%
Regeneron Pharmaceuticals, Inc. 3.10%
Amgen Inc 3.00%
Biogen Idec Inc., 2.90%
Actelion Ltd. 2.80%

Sectors weighting

Pharmaceuticals 95.70%
Fixed Interest 4.60%
Net Current Assets -0.30%

Regional weighting

North America Region 81.00%
Europe Developed ex-UK 11.00%
Japan 7.00%
Other Countries 3.00%
Asia exc Japan 0.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Base Currency GBX
  • Domicile UK
  • Share Price (p) 1300.00
  • Share Type Ordinary Share
  • ISIN GB0003385308
  • Shares Issued (M) 47
  • Market Capital (£M) 613.60
  • Gross Assets (£M) 736.75
  • Net Assets (£M) 670.97
  • TER (%) 0.73
  • Historic Dividend Yield (%) 1.14
  • Next Dividend Date 04 Dec 2014
  • Next Dividend (p) 8.00
  • Last AGM 24 Jul 2014
  • Next AGM 24 Jul 2015
  • Last Annual Report Date 16 Jun 2014
  • Next due Report Date  
  • Next due Report Type I/R
  • Objective:

  • To invest worldwide in pharmaceutical and biotechnology companies with the aim of achieving a high level of capital growth.
  • Management Group(s):

  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Alastair Smith Start: 10 Apr 2007
  • Samuel. D Isaly Start: 26 Feb 2009
  • Management Contract & Fees:

    The Manager receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to GBP150m, 0.20% p.a. of the market capitalisation in excess of GBP150m and up to GBP500m, and 0.125% p.a. of the market capitalisation in excess of GBP500m, plus a fixed amount equal to GBP 57,500 per annum. The notice period on the Management, Administration and Company Secretarial Agreement with Frostrow is 12 months, termination can be initiated by either party. Investment Manager is also entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any out-performance of the NAV over the benchmark index. At each quarterly calculation date any performance fee payable is based on the lower of: (i) the cumulative out-performance of the investment portfolio over the benchmark index as at the quarter end date; and (ii) the cumulative out-performance of the investment portfolio over the benchmark as at the corresponding quarter end date in the previous year.

Sorry, this link is not
quite ready yet